The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1494
May 9, 2016
View Complete Issue         Table of Contents 2019 
Odefsey - Another NNRTI Combination for HIV
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Odefsey - Another NNRTI Combination for HIV
May 9, 2016 (Issue: 1494)
The FDA has approved Odefsey (Gilead), a once-daily, fixed-dose combination of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Odefsey - Another NNRTI Combination for HIV
Article code: 1494c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.